Geode Capital Management LLC Sells 30,034 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Geode Capital Management LLC decreased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,015,327 shares of the biotechnology company’s stock after selling 30,034 shares during the quarter. Geode Capital Management LLC owned about 1.98% of Heron Therapeutics worth $4,615,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of HRTX. Argent Advisors Inc. bought a new position in shares of Heron Therapeutics during the fourth quarter worth $31,000. Cutter & CO Brokerage Inc. raised its stake in Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after buying an additional 13,600 shares during the period. Arkadios Wealth Advisors bought a new position in Heron Therapeutics during the fourth quarter worth about $76,000. Intech Investment Management LLC grew its stake in Heron Therapeutics by 61.8% in the fourth quarter. Intech Investment Management LLC now owns 58,242 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 22,254 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in shares of Heron Therapeutics by 456.5% in the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 84,205 shares in the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th.

Heron Therapeutics Price Performance

HRTX opened at $2.30 on Friday. The company has a market capitalization of $350.36 million, a price-to-earnings ratio of -12.78 and a beta of 1.39. The business’s 50-day moving average price is $2.12 and its two-hundred day moving average price is $1.79. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. Sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.